Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Enterprise Value for 6 consecutive years, with -$77.3 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value fell 2283.81% to -$77.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$77.3 million, a 2283.81% decrease, with the full-year FY2024 number at -$97.5 million, down 636.06% from a year prior.
- Enterprise Value was -$77.3 million for Q3 2025 at Inhibikase Therapeutics, up from -$87.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$3.2 million in Q3 2024 to a low of -$97.5 million in Q4 2024.
- A 5-year average of -$37.6 million and a median of -$26.5 million in 2022 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: tumbled 601525.64% in 2021, then soared 80.73% in 2024.
- Inhibikase Therapeutics' Enterprise Value stood at -$40.8 million in 2021, then skyrocketed by 43.44% to -$23.1 million in 2022, then soared by 42.51% to -$13.3 million in 2023, then crashed by 636.06% to -$97.5 million in 2024, then grew by 20.73% to -$77.3 million in 2025.
- Per Business Quant, the three most recent readings for IKT's Enterprise Value are -$77.3 million (Q3 2025), -$87.7 million (Q2 2025), and -$93.2 million (Q1 2025).